Kingswood Wealth Advisors LLC purchased a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned 0.12% of Brainstorm Cell Therapeutics at the end of the most recent reporting period.
Brainstorm Cell Therapeutics Price Performance
BCLI stock opened at $0.34 on Friday. Brainstorm Cell Therapeutics Inc. has a 1-year low of $0.13 and a 1-year high of $2.18. The company has a market capitalization of $23.72 million, a price-to-earnings ratio of -1.06 and a beta of 0.43. The business has a 50 day simple moving average of $0.46 and a two-hundred day simple moving average of $0.41.
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) last posted its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.02. Sell-side analysts anticipate that Brainstorm Cell Therapeutics Inc. will post -0.28 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Get Our Latest Research Report on Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Profile
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
Featured Stories
- Five stocks we like better than Brainstorm Cell Therapeutics
- What is the Dogs of the Dow Strategy? Overview and Examples
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- MarketBeat Week in Review – 6/24 – 6/28
- Stock Sentiment Analysis: How it Works
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Want to see what other hedge funds are holding BCLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Free Report).
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.